Crossref
Trofinetide Receives FDA Approval as First Drug for Rett Syndrome
JAMA · 2023
DOI: 10.1001/jama.2023.4003 ↗Kurz gefasst
Fachartikel in der Zeitschrift JAMA, 2023. Verfasst von Emily Harris. Hauptthemen laut MEDLINE: Drug Approval, Rett Syndrome, Central Nervous System Agents. Die Arbeit wurde bisher 16-mal zitiert (Crossref).
Abstract (Originalsprache)
Kein Abstract verfügbar.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Drug ApprovalRett SyndromeCentral Nervous System AgentsHumansGlutamatesUnited States Food and Drug AdministrationUnited States
Substanzen
GlutamatestrofinetideCentral Nervous System Agents
Zitieren
APA
Harris, E. (2023). Trofinetide Receives FDA Approval as First Drug for Rett Syndrome. JAMA. https://doi.org/10.1001/jama.2023.4003
Vancouver
Harris E. Trofinetide Receives FDA Approval as First Drug for Rett Syndrome. JAMA. 2023. doi:10.1001/jama.2023.4003
BibTeX
@article{Harris2023,
author = {Harris, Emily},
title = {Trofinetide Receives FDA Approval as First Drug for Rett Syndrome},
journal = {JAMA},
year = {2023},
doi = {10.1001/jama.2023.4003}
}
EUVIMED